LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Sarepta Therapeutics Inc

Suletud

SektorTervishoid

36.42 3.32

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.22

Max

36.69

Põhinäitajad

By Trading Economics

Sissetulek

-607M

-448M

Müük

86M

745M

P/E

Sektori keskmine

27.205

56.602

Aktsiakasum

-3.42

Kasumimarginaal

-60.08

Töötajad

1,372

EBITDA

142M

191M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+173.8% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-6.8B

3.6B

Eelmine avamishind

33.1

Eelmine sulgemishind

36.42

Uudiste sentiment

By Acuity

50%

50%

173 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Sarepta Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2025, 14:19 UTC

Suurimad hinnamuutused turgudel

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

20. juuni 2024, 23:05 UTC

Suurimad hinnamuutused turgudel

Sarepta Shares Soar 37% Following Expanded Approval for Elevidys

21. juuni 2024, 08:58 UTC

Peamised uudised

These Stocks Are Moving the Most Today: Microsoft, Nvidia, Trump Media, Sarepta, CarMax, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Sarepta Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

173.8% tõus

12 kuu keskmine prognoos

Keskmine 96.57 USD  173.8%

Kõrge 188 USD

Madal 40 USD

Põhineb 23 Wall Streeti analüütiku instrumendi Sarepta Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

23 ratings

18

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

N/A / 62.47Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Sentiment

By Acuity

173 / 382 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.